TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of refractory anemia with excess blasts or refractory anemia with excess blasts in transformation according to the French-American-British classification system for myelodysplastic syndromes (MDS) and a relatively high risk of acute myeloid leukemia (AML) transformation, with an International Prognostic Scoring System score of INT-2 or High.~* Be 18 years of age or older~* Have a life expectancy of at least 3 months~* Be unlikely to proceed to bone marrow or stem cell transplantation therapy following remission~* Have serum bilirubin levels less than or equal to 1.5 times the upper limit of normal range for the laboratory~* Have serum glutamic-oxaloacetic transaminase (aspartate aminotransferase) or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 times the upper limit of normal (unless these are considered to be related to transfusion-induced secondary hemosiderosis)~* Have serum creatinine levels less than or equal to 1.5 times the upper limit of normal~Exclusion Criteria:~* Secondary myelodysplastic syndromes (MDS)~* Prior treatment with azacitidine;~* Prior history of acute myeloid leukemia (AML);~* Malignant disease diagnosed within prior 12 months;~* Metastatic disease;~* Hepatic tumors;~* Radiation, chemotherapy, cytotoxic therapy for non-MDS conditions within prior 12 months;~* Prior transplantation or cytotoxic therapy to treat MDS;~* Serious medical illness likely to limit survival to 12 months or less;~* Treatment with erythropoietin or myeloid growth factors during prior 21 days or androgenic hormones during prior 13 days;~* Active HIV, viral hepatitis type B or C;~* Treatment with investigational drugs during prior 30 days;~* Within the 28-day screening period, documented red cell folate deficiency, as evidenced by red blood cell folate (not serum folate) or vitamin B12 deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
- Conventional Care (Type: ACTIVE_COMPARATOR): Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~One or more of the following:~1 Have 3 or more outpatient clinics visits for COPD (ICD-9) in the two years prior to enrollment.~2. Have been hospitalized with a primary discharge diagnosis (ICD-9) for COPD in the two years prior to enrollment.~3. Active use of inhaled beta-agonist and ipratropium bromide (or equivalent in combination inhalers like Combivent) in the 12 months prior to enrollment.~Plus~1. Have a future visit scheduled in one of the eligible primary care or chest clinics; and~2. Have airflow limitation~Exclusion Criteria:~1. If they have cognitive dysfunction, language barriers or severe psychiatric disorder that would preclude them from completing the questionnaires. This was assessed initially by the patients provider and by the research assistant during in-person interviews.~2. The provider taking care of their COPD does not participate.~3. Have a new diagnosis of COPD within the last month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Audit and Feedback
- Control (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically and biopsy confirmed non-neoplasia epithelial disorders of skin and mucosa of vulva.~* Patient must have a score of 5 or greater in the itching score table before treatment and the itching must last at least 6 months.~Exclusion Criteria:~* Patients with vulvovaginal or other gynecological trauma, acute inflammatory diseases and other acute illness~* Patients have been treated with any kind of topical therapy at the vulva within 12 weeks prior to participation in the study~* Patients with other serious diseases (e.g. liver or kidney diseases) that need immediate treatment~* Patients with atypical vulvar hyperplasia or vulvar cancer confirmed by biopsy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- treatment group (Type: EXPERIMENTAL): Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with refractory or relapsed multiple myeloma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (a measurement to determine participant's ability to perform daily activities)~* Adequate bone marrow reserve~* Adequate hepatic and renal function~* Ability to swallow capsules~* 3 weeks or more since prior chemotherapy and have recovered from prior toxicities~Exclusion Criteria:~* Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment~* Participants with prior treatment with other investigational agents with a similar anti-tumor mechanism~* Participants with other active/uncontrolled clinically significant illness~* Pregnant or nursing female participants~* Participants who received bortezomib within 3 months of start of this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vorinostat 200 mg + bortezomib 0.7 mg/m^2 (Type: EXPERIMENTAL): Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
- vorinostat 200 mg + bortezomib 0.9 mg/m^2 (Type: EXPERIMENTAL): Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
- vorinostat 300 mg + bortezomib 1.3 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 0.9 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 1.1 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
- vorinostat 400 mg + bortezomib 1.3 mg/m^2 (Type: EXPERIMENTAL): Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Micra Atrial TRacking Using A Ventricular AccELerometer 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has been implanted with a Micra TPS (Model MC1VR01) with remaining device longevity of 6 years or more or is expected to be implanted with a Micra TPS.~* Subject has history of AV block\*~* Subject is ≥ 18 years old and as per required local law.~* Subject (and/or witness as applicable per local regulations) provides signed and dated authorization and/or consent per institution and local requirements.~* Subject is willing and able to comply with the protocol. \*This includes subjects with normal sinus function and persistent 3rd degree AV block and subjects with other forms of AV block.~Exclusion Criteria:~* Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic Clinical Research Specialist.~* Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to MARVEL 2 study procedures).~* Subject meets any exclusion criteria required by local law (age or other).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode (Type: EXPERIMENTAL): Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~RA patients treated with adalimumab who satisfied the following conditions:~1. Paid worker (PW) RA patients who are engaged in paid work for more than 35 hours per week~2. Home worker (HW)~   * Category 1 unpaid workers; RA patients who are engaged in paid work for less than 35 hours per week~  * Category 2 unpaid workers; RA patients who perform basic activities of daily life (household duties, shopping, child caring, exercise, study, etc.) other than PW~Exclusion Criteria:~1. RA patients showing lowered basic activities of daily life, such as hospitalization and being bedridden~2. RA patients with a history of previous treatment with adalimumab

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 87 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* CD20-positive follicular non-Hodgkin's lymphoma (NHL)~* Documented partial or complete response a the end of induction treatment with rituximab~* Must have completed induction treatment, and received at least 1 dose of intravenous rituximab maintenance treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of less than and equal to (\<=) 2~* Life expectancy of greater than and equal to (\>=) 6 months~Exclusion Criteria:~* Histological evidence of transformation of NHL, or types of NHL other than follicular lymphoma~* Presence or history of central nervous system disease~* History of malignancy other than follicular NHL~* Recent major surgery (within 4 weeks prior to screening), excluding lymph node biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab IV 375 mg/m^2 (Stage 1: Cohort A) (Type: ACTIVE_COMPARATOR): None
- Rituximab IV 375 mg/m^2 (Stage 2: Cohort E) (Type: ACTIVE_COMPARATOR): None
- Rituximab SC 1400 mg (Stage 2: Cohort F) (Type: EXPERIMENTAL): None
- Rituximab SC 375 mg/m^2 (Stage 1: Cohort B) (Type: EXPERIMENTAL): None
- Rituximab SC 625 mg/m^2 (Stage 1: Cohort C) (Type: EXPERIMENTAL): None
- Rituximab SC 800 mg/m^2 (Stage 1: Cohort D) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Safety Study of ADS-5102 in PD Patients With LID

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed a current IRB/REB/IEC-approved informed consent form~* Completed all study visits in previous Adamas efficacy study or were ineligible for participation in previous Adamas studies due to having undergone prior deep brain stimulation.~* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria~* On a stable regimen of antiparkinson's medications at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily.~* History of peak dose dyskinesia that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator~Exclusion Criteria:~* Discontinued ADS-5102 in previous Adamas efficacy study due to intolerable or unacceptable AEs considered to be related to ADS-5102~* History of neurosurgical intervention related to Parkinson's disease, with the exception of deep brain stimulation~* History of seizures since completion of participation in previous Adamas studies or within 2 years~* History of stroke or TIA since completion of participation in previous Adamas studies or within 2 years~* History of cancer since completion of participation in previous Adamas studies or within 2 years, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer~* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening~* If female is pregnant or lactating~* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.~* Treatment with an investigational drug (other than ADS-5102) or device within 30 days prior to screening~* Treatment with an investigational biologic within 6 months prior to screening~* Current or planned participation in another interventional clinical trial

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ADS-5102 (Type: EXPERIMENTAL): amantadine HCl extended release

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Men or women ≥ 18 and ≤ 75 years of age at time of screening~2. Stable moderate to severe plaque psoriasis for at least 6 months before baseline~3. Moderate to severe psoriasis defined at screening and baseline by:~   Body surface area (BSA) affected by plaque psoriasis of 10% or greater, and PASI score of 12 or greater, and static physician's global assessment score of 3 or greater~4. No known history of active tuberculosis~5. Subject is a candidate for systemic therapy or phototherapy procedures~6. Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy~Exclusion Criteria:~1. Forms of psoriasis or other skin conditions at the time of the screening visit (eg, eczema)~2. Ongoing use of prohibited treatments~3. Prior use of 2 or more biologics for treatment of psoriasis~4. Previous receipt of adalimumab or a biosimilar of adalimumab~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABP 501 (Type: EXPERIMENTAL): Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48.
- Adalimumab (Type: ACTIVE_COMPARATOR): Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:(For randomized trial)~1. Non-pregnant English-speaking women~2. 18 yo or older~3. Overactive Bladder (OAB) Awareness scores ≥ 8~4. 3 UUI episodes/week for ≥ 3 months~Exclusion Criteria: (For Randomized trial)~1. Women with a history of neurologic diseases such as Multiple Sclerosis, Parkinson's disease, stroke, or dementia~2. History of schizophrenia or untreated bipolar disorder or current drug or alcohol dependence~3. Women who have taken anticholinergic medications for UUI within the last 3 weeks (women who have taken anti-cholinergics for UUI but discontinued them \> than 3 weeks ago may participate in the study) or have a sacral neuromodulator in place to treat UUI or have received Onabotulinum toxin A in the last 12 months to treat UUI~4. Contraindications to anticholinergic medications (untreated narrow angle glaucoma, significant urinary retention or gastric retention)~5. Pregnant women or lactating women, women who plan to become pregnant in the next year, or pre-menopausal women unwilling to use contraception if engaging in sexual relations during the year of study participation (hysterectomy is considered to be a form of contraception)~6. Untreated urinary tract infection~7. Prolapse which extends past the hymen (POP-Q points of ≥ 1+) which may be responsible for UUI symptoms~8. Women who cannot keep the majority of the study therapy appointments or those without reliable contact phone numbers or methods of communication with the study personnel.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Anticholinergic medications (Type: ACTIVE_COMPARATOR): Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
- Hypnotherapy (Type: ACTIVE_COMPARATOR): Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced ovarian cancer with positive BRCA1 or BRCA2 status~* Progressive or recurrent disease after platinum-based chemotherapy~* Measurable disease by RECIST~Exclusion Criteria:~* Previous anthracycline treatment~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD2281 Oral 200 mg BID
- 2 (Type: ACTIVE_COMPARATOR): Liposomal Doxorubicin
- 3 (Type: EXPERIMENTAL): AZD2281 Oral 400 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete